RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.995
-0.205 (-9.32%)
At close: Sep 9, 2026, 4:00 PM EDT
2.000
+0.005 (0.25%)
Pre-market: Sep 10, 2026, 4:44 AM EDT
RenovoRx Employees
RenovoRx had 17 employees as of December 31, 2025. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$116,235
Profits / Employee
-$722,647
Market Cap
90.03M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 7 | 70.00% |
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Mar 31, 2024 | 10 | 0 | - |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Sep 30, 2023 | 10 | 0 | - |
| Jun 30, 2023 | 10 | 0 | - |
| Mar 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Sep 30, 2022 | 10 | 0 | - |
| Jun 30, 2022 | 10 | 2 | 25.00% |
| Mar 31, 2022 | 10 | 4 | 66.67% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Sep 30, 2021 | 10 | 1 | 11.11% |
| Jun 30, 2021 | 8 | - | - |
| Mar 31, 2021 | 6 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| PMV Pharmaceuticals | 54 |
| Oncolytics Biotech | 29 |
| Cognition Therapeutics | 14 |
| Atara Biotherapeutics | 10 |
| Aldeyra Therapeutics | 6 |
RNXT News
- 7 days ago - RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th - GlobeNewsWire
- 12 days ago - RenovoRx price target raised to $14.50 from $14 at Ascendiant - TheFly
- 15 days ago - RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial - TheFly
- 15 days ago - RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 19 days ago - RenovoRx regains compliance with Nasdaq - TheFly
- 19 days ago - RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 20 days ago - RenovoRx receives notice of allowance for new RenovoCath U.S. patent - TheFly
- 20 days ago - RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - GlobeNewsWire